PHARMACEUTICAL RESEARCH FUNDAMENTALS EXPLAINED

Antibody avidity meets numerous myeloma In the ongoing hunt for modern treatments to combat refractory and relapsed most cancers, new preclinical function in numerous myeloma shows that escalating binding avidity by concentrating on two antigens in a single T cell-partaking trispecific antibody boosts anti-tumor action and lowers the chance of tumo